Search
Clofedanol
go.drugbank.com/drugs/DB04837ApprovedWithdrawnClofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States.
Mixtures: Certuss-D, biclora-DCediranib
go.drugbank.com/drugs/DB04849InvestigationalThe novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. … It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
Categories: Heterocyclic Compounds, 2-RingDronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigational[T28] Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. … A safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone.[L8800]
Categories: Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide, N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamideLorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnThis decision was based on the results of a clinical trial assessing the risk of heart-related problems that found that patients treated with lorcaserin may have a higher risk of cancer. … Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingOritavancin
go.drugbank.com/drugs/DB04911ApprovedInvestigational[A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. … [L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP2C19 InhibitorsPermethrin
go.drugbank.com/drugs/DB04930ApprovedInvestigationalA pyrethroid insecticide commonly used in the treatment of lice infestations and scabies. It is a yellow to light orange-brown, low melt-ing solid or viscous liquid.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersSynonyms: (3-Phenoxyphenyl)methyl (±)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate, 3-(2,2-Dichloroethenyl)-2,2-dimethylcyclopropane carboxylic acid, (3-phenoxyphenyl) methyl esterLucanthone
go.drugbank.com/drugs/DB04967InvestigationalIt is currently being tested as a radiation sensitizer.
Categories: Heterocyclic Compounds, 3-RingSynonyms: 1-((2-(Diethylamino)ethyl)amino)-4-methylthioxanthen-9-one, 1-{[2-(diethylamino)ethyl]amino}-4-methylthioxanthen-9-oneCanfosfamide
go.drugbank.com/drugs/DB04972InvestigationalCanfosfamide is an active agent in chemotherapy-resistant ovarian cancer.
Belinostat
go.drugbank.com/drugs/DB05015ApprovedInvestigationalBelinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. … It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic IndexSynonyms: (2E)-N-HYDROXY-3-(3-(PHENYLSULFAMOYL)PHENYL)PROP-2-ENAMIDE, 2-PROPENAMIDE, N-HYDROXY-3-(3-((PHENYLAMINO)SULFONYL)PHENYL)-Mitoquinone
go.drugbank.com/drugs/DB05063Investigational-- where they accumulate up to a thousand fold. … In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct molecular link between mitochondrial dysfunction and the pathogenesis of Parkinson's disease.